Ovalicin attenuates atopic dermatitis symptoms by inhibiting IL-31 signaling and intracellular calcium influx

Sung-Hyun Hwang¹,², Yeseul Yang¹,², Yeji Jeong¹,², Yongbaek Kim¹,³,✉

¹Laboratory of Clinical Pathology, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea; ²The Brain Korea 21 Future Veterinary Medicine Leading Education and Research Center, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea; ³Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea.

Abstract

Atopic dermatitis (AD) is a common skin disorder difficult to be treated with medication. This study investigated the potential of ovalicin extracted from Cordyceps militaris for the treatment of AD using in vitro and in vivo models. We found that, in canine macrophage cell line DH82, lipopolysaccharide (LPS) upregulated the expression of genes associated with inflammation and pruritic responses through activating calcium and interleukin-31 (IL-31) signaling, and the upregulation could be suppressed by ovalicin, with an effect significantly stronger than dexamethasone. Ovalicin also reduced the expression of IL-31 downstream genes, including JAK2 (Janus kinase 2), TRPV1 (transient receptor potential vanilloid receptor-1), and HRH2 (histamine receptor H2). Ovalicin significantly alleviated the allergic symptoms in the AD mouse model. Histologically, the number of macrophages and mast cells infiltrated in the dermis was significantly reduced by ovalicin treatment. In the skin tissue of AD mice, reduction of IL-31 receptor was observed in the ovalicin treated group compared to the group without ovalicin treatment. To our knowledge, this is the first study to elucidate the anti-atopic mechanism of ovalicin, which could be an alternative to steroidal drugs commonly used for AD treatment.

Keywords: ovalicin, IL-31, pruritus, inflammation, calcium, atopic dermatitis

Introduction

Atopic dermatitis (AD) is characterized by pruritus, a cardinal symptom accompanying dermatologic changes to worsen the quality of life[1]. In AD patients, scratches make the skin barrier vulnerable to infection[2–3]. Antipruritic agents with anti-inflammatory effects are beneficial for AD patients. Steroidal drugs are widely used to relieve pruritus, but have severe side effects, such as petechiae, telangiectasia, muscle atrophy, and liver damage[4–6]. Efforts to find their alternatives have been explored.

Ovalicin, extracted from an entomopathogenic fungus Metarhizium anisopliae in Cordyceps militaris, is an active ingredient of antidandruff and antibacterial agents[7]. Ovalicin is purified by filtration,

✉Corresponding author: Yongbaek Kim, Laboratory of Clinical Pathology, College of Veterinary Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea. Tel/Fax: +82-2-880-1273/+82-2-873-1213, E-mail: yongbaek@snu.ac.kr.

Received: 22 January 2021; Revised: 09 April 2021; Accepted: 14 April 2021; Published online: 16 June 2021

© 2021 by the Journal of Biomedical Research. https://doi.org/10.7555/JBR.35.20210012
Ovalicin attenuates atopic dermatitis symptoms

449

extraction with ethyl acetate, vacuum evaporation, and elution in florisil-packed chromatography[8]. Recent studies have shown that ovalicin relieves AD symptoms in mouse models; however, the molecular mechanism underlying its antipruritic effects is unclear.

In AD patients, skin tissue has deviated immune reactions to T helper 2 (Th2) cells. When exposed to an allergen, interleukin (IL)-31 produced from Th2 cells conjugates with its receptor[9]. In turn, the IL-31 communicates with the dorsal root ganglion and induces a pruritic response[10]. Comparative analysis of the pruritic response in wild-type and IL-31 knockout mice shows a lower frequency of scratching behavior in Il31 knockout mice, while the inflammatory responses are comparable[11]. A higher level of IL-31 and its dimeric receptors, IL-31RA and oncostatin M receptor (OSMR), is detected in AD patients compared to healthy individuals[12]. Transient receptor potential cation channel 1 (TRPV1) is upregulated by histamine via phospholipase A2 activation, and subsequently induces scratching behavior[13]. TRPV1 also induces the calcium influx for histamine release. However, the function of TRPV1 in IL-31 signaling is unclear.

In this study, we investigated the effects of ovalicin on DH82 cells and in 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model, and found that ovalicin may function as a potent antipruritic agent by repressing IL-31 signaling.

Materials and methods

Cell culture

The canine macrophage cell line, DH82, was kindly provided by Dr. Yun sang Cho (Animal and Plant Quarantine Agency, Republic of Korea). DH82 cells were cultured in Roswell Park Memorial Institute Medium (Gibco-Life Technology, USA) containing 100 µg/mL of penicillin/streptomycin (Gibco), 1 mmol/L of sodium pyruvate (Sigma-Aldrich, USA), 10 mmol/L of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Sigma-Aldrich), 10 mmol/L of sodium carbonate (Sigma-Aldrich), and 10% fetal bovine serum (Corning, USA).

Reagents

Purified ovalicin was provided by Mycoplus Inc. (Republic of Korea) and diluted as described previously[8]. Ovalicin was dissolved in complete medium. DH82 cells were treated with 10 µmol/L ruxolitinib (Ruxo; Selleckchem, USA), a Janus kinase (JAK) inhibitor, for 24 hours. Intracellular calcium was chelated using 10 µmol/L BAPTA-AM (Calbiochem, USA) for 24 hours.

Cell viability assay

DH82 cells (1×10^4) were treated with ovalicin, lipopolysaccharide (LPS; Sigma-Aldrich), and/or dexamethasone (Dexa; Sigma-Aldrich) for 3 days. After treatment, cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich) for 2 hours at 37 °C. Then, formazan was dissolved by dimethyl sulfoxide and 2-propanol mixture in a 1:9 ratio, and absorbance was measured at a wavelength of 570 nm using a microplate reader (BioTek Epoch, Spain).

Real-time RT-PCR

Total RNA was extracted using Trizol reagent (Ambion, USA), followed by quantitation using an Epoch microplate spectrophotometer (BioTek Epoch). Next, complementary DNA (cDNA) was synthesized using 500 ng of total mRNA and a commercial cDNA synthesis kit (Enzymics, Republic of Korea). The SYBR Green reverse transcriptase PCR (RT-PCR) kit (Enzymics) was used to determine the expression levels of IL4, IFNG, IL31RA, OSMR, TRPV1, and HRH2 mRNA encoding IL-4, interferon-γ (IFN-γ), IL-31RA, OSMR, TRPV1, and histamine receptor H2 (HRH2), respectively. All primers are listed in Supplementary Table 1 (available online). Data were analyzed using the 2^(-ΔΔCt) method[14].

Measurement of reactive oxygen species

Intracellular reactive oxygen species (ROS) were measured using 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA; Molecular Probes, Invitrogen, USA) according to the manufacturer's instructions. Briefly, DH82 cells were harvested and treated with 2.5 µmol/L of H2DCFDA and incubated for 30 minutes at 37 °C in the dark. Subsequently, the cells were washed thrice with phosphate-buffered saline (PBS) and immediately analyzed by flow cytometry using FACSVerse (Becton Dickinson, USA).

Measurement of IL-31 in cell culture medium by enzyme-linked immunosorbent assay

The cell culture medium was collected and centrifuged at 3000 g for 3 minutes to eliminate cell debris. The IL-31 level was measured using an enzyme-linked immunosorbent assay kit (MyBioSource, USA) according to the manufacturer's instructions. Briefly, standards and samples were plated in each well with a balanced solution and a conjugate solution. After washing thrice, a substrate solution was added and incubated for 15 minutes at
37 °C. Next, a stop solution was added, and the optical density was measured at a wavelength of 450 nm using the Epoch microplate spectrophotometer (BioTek Epoch). The expression level of IL-31 was calculated according to a standard curve.

**Western blotting assay**

Proteins of DH82 cells were extracted using Ez RIPA buffer (Atto, Japan) and quantitated it using Bradford assay (Bio-Rad Laboratories, USA). Next, 10 μg of the whole lysate in each sample was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Amersham, GE Healthcare, USA). Blocking buffer (5% skim milk in PBS with 0.1% Tween 20) was added for 1 hour at room temperature. Primary antibodies, including total-STAT3 (Cell Signaling, USA), p-STAT3 (Cell Signaling), JAK2 (Cell Signaling), inducible nitric oxide synthase (iNOS; Santa Cruz Biotechnology, USA), cyclooxygenase-2 (COX2; Cell Signaling), nuclear factor kappa B (NF-κB; Santa Cruz Biotechnology), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology), were added in a dilution of 1:1000 and incubated for 16 hours at 4 °C. Then secondary anti-rabbit or anti-mouse antibody conjugated with horseradish peroxidase (Santa Cruz Biotechnology) was added, and bands were detected using the Luminata Forte HRP substrate (Millipore, USA).

**Calcium measurement**

A total of 1×10⁶ DH82 cells were seeded in a confocal dish (SPL, Republic of Korea) and treated with 5 μmol/L Fluo-4AM (Molecular Probes, Invitrogen, Spain), followed by incubation for 30 minutes in 37 °C in the dark. Nuclei were stained by NucBlue Live Cell Stain (Life Technologies, USA), and fluorescence was detected using fluorescence microscopy (Thermo Fisher Scientific, USA) after gentle washing thrice with PBS.

**DNCB-induced atopic dermatitis mouse model**

All animal experiments were approved by the Institutional Animal Care and Use Committee at Seoul National University, Republic of Korea (SNU-180327-1-2). Female BALB/C mice aged 5 weeks were purchased from Jungang Lab Animal Inc. (Republic of Korea) and shaved their back skin. To establish the AD model, 1% of DNCB solution was painted twice on the shaved back skin, and after 2 days, 0.1% DNCB solution was applied. The DNCB-treated AD mice were administered 1 and 10 μg/mL of ovalicin daily for 5 days. As a negative control, 10 μg/mL of ovalicin was painted on the shaved back skin of DNCB-untreated mice. After day 5, the dermatitis lesion score was measured from 0 to 4 based on the degree of hemorrhage, scarring, edema, and erosion[15].

**Histological analysis**

Skin tissues from mice were collected and fixed in 10% neutral buffered formalin solution. The fixed tissues were routinely processed, embedded in paraffin, and cut into 3-μm-thick slices. Sections on glass slides were prepared and stained with hematoxylin and eosin (H&E) and toluidine blue (TB). Histopathological analysis was performed by a veterinary pathologist according to published criteria[10].

**Immunohistochemistry**

IL-31 expression in paraffin-embedded skin tissues was assessed by immunohistochemistry (IHC)[10]. Briefly, the prepared glass slides were deparaffinized by incubating in xylene solution, followed by hydration using serial alcohols, antigen retrieval using 1× citrate buffer (Sigma-Aldrich), and blocking using 2.5% normal horse serum (Vector Labs, USA). After washing with PBS, the slides were incubated overnight with ionized calcium-binding adaptor molecule 1 (IBA1) (Fujifilm Wako Chemicals, USA) and IL-31 receptor antibody (Santa Cruz Biotechnology) containing 2.5% normal horse serum and then incubated with HRP-conjugated horse anti-rabbit secondary antibody (Vector Labs) for 2 hours. After treatment with 3,3′-diaminobenzidine solution (Vector Labs), the slides were counterstained using hematoxylin, dehydrated in serial alcohols, and mounted using a xylene-based solution.

**Statistical analysis**

Statistical significance was determined using one-way analysis of variance (ANOVA) and Tukey’s test (pairwise) with GraphPad Prism 5 software (USA). P<0.05 was considered statistically significant.

**Results**

**Optimization of ovalicin and LPS concentrations**

To determine the nontoxic concentration of ovalicin, DH82 cells were treated with 1, 10, 20, 40, 100, and 200 μg/mL of ovalicin for 24, 48, and 72 hours, respectively, and the cell viability was assessed. The results showed that DH82 cell viability decreased dose-dependently after ovalicin treatment (Fig. 1A). At 24 and 48 hours, more than 90% of cells survived
after treatment with 1 and 10 μg/mL of ovalicin (Fig. 1A). Therefore, 2, 4, and 10 μg/mL of ovalicin were used for the subsequent experiments. DH82 cells were treated with LPS for 1 day, followed by evaluation of cell viability and IL4 mRNA expression. After treatment with 500 ng/mL of LPS, cell viability was comparable to that after PBS treatment, while IL4 mRNA expression significantly increased (Fig. 1B and C). DH82 cells were treated with 50, 100, 200, 500, and 1000 μmol/L Dexa for 1 day, and 25 μmol/L of Dexa was selected for further experiments based on the cell viability assay results (Fig. 1D).

Ovalicin mitigates the effects of LPS treatment on DH82 cells

Pretreatment with LPS augments the proliferation after few days by NF-κB signaling-induced stimulation, leading to disorder of immune responses. To examine if ovalicin suppressed the LPS-induced stimulation in macrophages, DH82 cells were challenged with 2, 4, and 8 μg/mL ovalicin or Dexa for 1 day after pretreatment with 500 ng/mL LPS for 1 day, and the viability was assessed. LPS pretreatment increased cell viability compared to LPS-untreated cells, but ovalicin treatment decreased cell viability dose-dependently (Fig. 2A). Intriguingly, the decrease in cell viability after 10 μg/mL ovalicin treatment was more than that after 25 μmol/L Dexa treatment. LPS-induced upregulation of IL4 and IFNG mRNA expression was significantly attenuated after ovalicin treatment (Fig. 2B and C). In addition, the inhibition of their mRNA levels after 10 μg/mL ovalicin treatment was more than that after 25 μmol/L Dexa treatment.

Ovalicin inhibits IL-31 expression and its downstream signaling

LPS treatment of DH82 cells increased IL-31 expression compared to LPS-untreated cells, but ovalicin treatment significantly inhibited IL-31 expression more than Dexa treatment did (Fig. 3A). In addition, ovalicin treatment of LPS-pretreated DH82 cells decreased the mRNA expression of IL-31 dimeric receptors, IL31RA and OSMR (Fig. 3B and C). Compared to Dexa treatment, the mRNA expression levels of these receptors were significantly decreased after 4 and 10 μg/mL ovalicin treatment. Notably, ovalicin treatment decreased the expression of IL31RA more markedly than that of OSMR. Furthermore, downstream molecules of IL-31 signaling, JAK2 and p-STAT3, were increased after LPS treatment compared to LPS-untreated cells, which was inhibited by ovalicin treatment dose-dependently (Fig. 3D).

![Fig. 1 Optimization of ovalicin and LPS concentrations. A: Viability of DH82 cells treated with 0–200 μg/mL of ovalicin for up to 3 days. Data are presented as mean±SEM (n=8). B: Viability of DH82 cells treated with 0–2000 ng/mL of LPS for 1 day. Data are presented as mean±SEM (n=8). C: Transcription level of IL4 in DH82 cells treated with 0–2000 ng/mL of LPS for 1 day. Data are presented as mean±SEM (n=4). **P<0.01 and ***P<0.001 vs. untreated DH82 cells. D: Viability of DH82 cells treated with 0–1000 μmol/L Dexa for 1 day. Data are presented as mean±SEM (n=8). Statistical analysis was conducted by ANOVA and Tukey's test (pairwise) for comparison with samples. PBS: phosphate-buffered saline; LPS: lipopolysaccharide; Dexa: dexamethasone.](image-url)
Ovalicin suppresses the expression of pruritus-related genes by inhibiting calcium influx

To examine the expression of pruritus-related genes, TRPV1 and HRH2, we treated LPS-pretreated DH82 cells with ovalicin. Ovalicin treatment significantly inhibited the LPS pretreatment-induced increased mRNA expression of these genes, and the decrease was more evident than that after Dexa treatment (Fig. 4A and B). Ruxo, a selective JAK2 inhibitor, decreased the mRNA expression of TRPV1 and HRH2 in LPS-pretreated DH82 cells, but the inhibitory effect was lower than that after ovalicin treatment.

LPS treatment enhanced the calcium influx compared to LPS-untreated cells in DH82 cells, which was attenuated by treatment with 10 μg/mL of ovalicin (Fig. 4C). The effect of ovalicin in LPS-pretreated cells was stronger than that of either Dexa or Ruxo treatment, and Ruxo inhibited calcium influx more effectively than Dexa did (Fig. 4C). To determine the effect of calcium influx on IL-31 signaling and pruritus-related genes, we chelated intracellular calcium by BAPTA-AM treatment. In DH82 cells, intracellular calcium was significantly chelated by 10 μmol/L BAPTA-AM treatment for 1 day (Supplementary Fig. 1, available online). Treatment of LPS-pretreated cells with 10 μg/mL of ovalicin inhibited the mRNA expression of IL31RA, TRPV1, and HRH2 more significantly than Ruxo treatment did (Fig. 4D). DH82 cells treated with 10 μmol/L BAPTA-AM were used as a positive control for calcium chelation.

Ovalicin shows anti-inflammatory effects in LPS-pretreated DH82 cells

The expression of inflammatory markers, including iNOS, COX2, and NF-κB, was enhanced after LPS treatment, which was inhibited by ovalicin treatment (Fig. 5A). Although Dexa treatment decreased the expression of these genes in LPS-pretreated cells, the degree of decrease was less than that by ovalicin treatment (Fig. 5B). Likewise, the mean fluorescence intensity of ROS in LPS-pretreated cells was mitigated after ovalicin treatment dose-dependently (Fig. 5C).

Ovalicin relieves pruritic lesions through inhibited IL-31 signaling in the DNCB-induced AD mouse model

Histological analysis of skin tissue in the DNBC-induced AD mouse model showed epidermal detachment and inflammation with loss of hair follicles. Ovalicin treatment relieved pruritic lesions through enhanced re-epithelialization and granulation tissue formation (Fig. 6A). In control mice, ovalicin treatment did not cause any morphologic change in the skin. IL-31 is also produced from macrophages by stimulation and conjugates with its receptor on mast cells to release histamine, leading to scratching behavior[11,19]. To evaluate the infiltrated macrophages in the mouse skin, we performed IHC staining for IBA1. Compared to the DNBC-untreated control mice, the macrophages positive for IBA1 were easily detected in the dermis of DNBC-induced AD mice. And the number of IBA1 positive macrophages was dramatically decreased by ovalicin treatment dose-dependently (Supplementary Fig. 2A, available online). TB staining of skin tissue showed that ovalicin treatment significantly decreases the number
of infiltrated mast cells in the DNCB-induced AD mouse model (Fig. 6B). Lesion scores compiling the extent of hemorrhage, scarring, edema, and erosion were comparable in DNCB-untreated control mice regardless of ovalicin treatment. In contrast, lesion scores in DNCB-treated AD mice were significantly higher compared to DNCB-untreated control mice, and the scores were significantly lower in the ovalicin-treated group (Fig. 6C). Additionally, albumin and total protein were higher in DNCB-treated AD mice than in DNCB-untreated control mice, which was reversed after ovalicin treatment (Table 1). Likewise, treatment of DNCB-treated AD mice with ovalicin enhanced the weight and mitigated percentage of neutrophil, monocyte, and eosinophil compared to non-treatment (Supplementary Fig. 2B and C, available online).

In DNCB-treated AD mice, ovalicin treatment decreased the mRNA expression of TRPV1 and HRH2 compared to AD mice without ovalicin treatment.
Compared to DNCB-untreated control mice, higher IL-31 expression was detected in the serum of DNCB-treated AD mice, and this increase was suppressed by ovalicin treatment dose-
Ovalicin attenuates atopic dermatitis symptoms

Fig. 5 Anti-inflammatory effect of ovalicin on LPS-pretreated DH82 cells. A: Expression of iNOS, COX2, NF-κB, and GAPDH in DH82 cells treated with 500 ng/mL LPS, ovalicin, and/or 25 μmol/L Dexa. B: Densitometric analysis of iNOS, NF-κB, and COX2 expression, using ImageJ, which was normalized by the value of GAPDH expression. Error bars indicate SEM (n=3). **P<0.01 vs. LPS-pretreated DH82 cells. ***P<0.001 vs. LPS-pretreated DH82 cells with Dexa. C: Representative histogram showing H2DCFDA staining in DH82 cells treated with 500 ng/mL LPS, ovalicin, and/or 25 μmol/L Dexa. Error bars indicate SEM (n=3). **P<0.01 and ***P<0.001 vs. LPS-pretreated DH82 cells. Statistical analysis was conducted by ANOVA and Tukey's test (pairwise) for comparison with samples. LPS: lipopolysaccharide; Dexa: dexamethasone.

dependently (Fig. 6F). Analogously, IHC staining of skin tissue revealed significantly higher expression of IL-31R in DNCB-treated AD mice than in DNCB-untreated control mice, which was decreased after ovalicin treatment (Fig. 6F).

Discussion

AD is an inflammatory skin disease and commonly occurs under sensitization to environmental allergens, such as grass, pollen, dust, and mites. AD patients have a quality of life worsened by pruritus, chronic inflammation, and secondary viral and bacterial infections[10]. In AD pathogenesis, macrophages play a crucial role and recognize the pathogen-associated molecular patterns by Toll-like receptors (TLRs). Activated macrophages produce various chemokines, such as IFN, IL-1, and IL-4, leading to recruitment of circulating monocytes and lymphocytes to skin lesions[20]. In addition, M2 polarization of macrophages by Th2 immunity stimulates IL-31 secretion in the dermis, culminating in pruritus[21]. However, the molecular mechanism of macrophages in AD pathogenesis, especially in the development of pruritus and inflammation, is unclear. In this study, we demonstrated that ovalicin shows antipruritic and anti-inflammatory effects by inhibiting IL-31 signaling and calcium influx in macrophages and the DNCB-induced AD mouse model.

To relieve pruritus in AD patients, various drugs, including steroidal drugs, have been developed, but their clinical applications are restricted because of severe side effects. Corticosteroids inhibit the release of cytokines by the activation of glucocorticoid
receptors and decrease local inflammation and pruritus\(^\text{[22]}\). However, their usage in case of generalized skin diseases is not recommended because of cutaneous side effects such as atrophy, acne, and telangiectasia\(^\text{[23]}\). Dexamethasone is widely used for the alleviation of pruritus in AD patients, but it induces topical burning, itching, and tingling\(^\text{[24]}\). Topical calcineurin inhibitors and antihistamine drugs inhibit pruritus in AD patients by T-cell inactivation, but these drugs also cause side effects, including localized burning and stinging\(^\text{[25–26]}\). In contrast, herbal medicines efficiently improve AD symptoms and exert fewer side effects\(^\text{[27]}\). This study showed that ovalicin alleviates AD symptoms in a DNCB-induced model.

\(\text{**ND**: 2,4-dinitrochlorobenzene; H&E: hematoxylin and eosin. Statistical analysis was conducted by ANOVA and Tukey’s test (pairwise) for comparison with samples. AD: atopic dermatitis; DNCB: 2,4-dinitrochlorobenzene.}\)

\(\text{Fig. 6  Effect of ovalicin on histopathologic lesions and IL-31 signaling in the DNCB-induced AD mouse model. A and B: Representative images of skin tissue stained with H&E and TB in DNCB-untreated control and 0.1% DNCB solution-treated AD mice with/without ovalicin treatment. Scale bar: 200 μm. C: Mean lesion scores in the skin of DNCB-untreated control and 0.1% DNCB solution-treated AD mice with/without ovalicin treatment. The lesion scores of the mouse skin tissue were from 0 to 3 on the basis of the extent of hemorrhage, scarring, edema, and erosion. Error bars indicate SEM (n=5). **P<0.01 and ***P<0.001. D: Transcription levels of TRPV1 and HRH2 in skin tissue from DNCB-untreated control and 0.1% DNCB solution-treated AD mice with/without ovalicin treatment. Error bars indicate SEM (n=5). **P<0.01 and ***P<0.001 vs. DNCB-untreated control mice without ovalicin treatment. E: Concentration of IL-31 in serum of DNCB-untreated control and 0.1% DNCB solution-treated AD mice with/without ovalicin treatment. Error bars indicate SEM (n=5). ***P<0.001 vs. DNCB-untreated control mice without ovalicin treatment. F: Representative immunohistochemical staining for IL-31R in skin tissue of DNCB-untreated control and 0.1% DNCB solution-treated AD mice with/without ovalicin treatment. Scale bar, 200 μm. DNCB: 2,4-dinitrochlorobenzene; H&E: hematoxylin and eosin. Statistical analysis was conducted by ANOVA and Tukey’s test (pairwise) for comparison with samples. AD: atopic dermatitis; DNCB: 2,4-dinitrochlorobenzene.}\)
AD mouse model by inhibiting IL-31 signaling and the inflammatory response more than Dexa does.

Ovalicin is a herbal medicine extracted from _C. militaris_ and is commonly used to control schizonts and parasite growth[7,28]. In compound 48/80-induced AD mice model, purified ovalicin alleviated AD symptoms[8], but the underlying molecular mechanism is unclear. In this study, we showed that ovalicin inhibits IL-31-signaling with decreased expression of pruritus-related genes, including TRPV1 and HRH2, in LPS-pretreated macrophages. TRPV1 plays a critical role in IL-31-induced scratching behavior and augments the intracellular calcium influx[12,29]. To the best of our knowledge, this is the first study to demonstrate that ovalicin inhibits calcium influx by inhibiting TRPV1, resulting in the suppression of IL-31 signaling in macrophages. The antipruritic efficacy of ovalicin is stronger than that of Dexa. Likewise, in our DNCB-induced AD mouse model, ovalicin treatment mitigated pruritic symptoms and decreased mast cell infiltration through attenuating IL-31-signaling. However, the effect of ovalicin on other immune players is unclear, which warrants further studies.

Scratching behavior due to pruritus induces severe inflammation, potentially leading to infection, cancer, neurologic, and endocrine disorders[30]. As a positive loop, severe inflammation aggravates pruritus through excessive production of Th2-type cytokines, including IL-31, IL-4, and IL-13[32]. Therefore, an anti-pruritic drug for AD treatment is essential for attenuating inflammation. Conjugation of TLRs with LPS plays a crucial role in the inflammatory response and activates transcription factors, such as NF-kB, interferon regulatory factors, and activation protein 1[33]. In addition, IL-31 administration in mice enhances the inflammation with recruitment of monocytes and lymphocytes, resulting in thickening of the skin barrier[35]. Our data showed that ovalicin treatment decreases inflammatory molecules, such as ROS, iNOS, COX2, and NF-κB, in LPS-pretreated DH82 cells more than Dexa treatment does. Analogously, inflammatory lesions in the DNCB-induced AD mouse model were significantly relieved by ovalicin treatment.

This study illustrated that purified ovalicin significantly improves pruritic symptoms of AD by inhibiting IL-31 signaling with inhibition of downstream genes in LPS-pretreated macrophages and the DNCB-induced AD mouse model. Our data indicate that ovalicin has better efficacy in the management of AD symptoms than Dexa and can be developed as an alternative treatment. Further characterization of the ovalicin efficacy in AD patients is warranted. However, the systemic toxicological research of ovalicin treatment in animal models is limited and warrants further study.

### Acknowledgments

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (Grant No. 2020R1A2C1010215) and the Brain Korea 21 Future Veterinary Medicine Leading Education and Research Center, College of Veterinary Medicine, Seoul National University.

### References

[1] Hong J, Buddenkotte J, Berger TG, et al. Management of itch in atopic dermatitis[J]. SeminCutan Med Surg, 2011, 30(2): 71–86.

[2] Wong LS, Wu T, Lee CH. Inflammatory and noninflammatory itch: implications in pathophysiology-directed treatments[J]. Int J Mol Sci, 2017, 18(7): 1485.
Ankers JM, Awais R, Jones NA, et al. Dynamic NF-κB and E2F interactions control the priority and timing of inflammatory signalling and cell proliferation[J]. Elife, 2016, 5: e10473.

Yamaoka K, Okayama Y, Kaminuma O, et al. Proteomic approach to FceRI aggregation-initiated signal transduction cascade in human mast cells[J]. Int Arch Allergy, 2009, 149(51): 73–76.

Jou IM, Lin CF, Tsai KJ, et al. Macrophage-mediated inflammatory disorders[J]. Mediators Inflamm, 2013, 2013: 316482.

Hashimoto T, Kursewicz CD, Frey RA, et al. Mechanisms of itch in stasis dermatitis: significant role of IL-31 from macrophages[J]. J Invest Dermatol, 2020, 140(4): 850–859.

Elmariiah SB, Lerner EA. Topical therapies for pruritus[J]. Semin Cutan Med Surg, 2011, 30(2): 118–126.

Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch[M]/Cowan A, Yosipovitch G. Pharmacology of Itch. Berlin Heidelberg: Springer, 2015: 337–356.

Perron G, Dolbec P, Germain J, et al. Perineal pruritus after iv dexamethasone administration[J]. Can J Anaesth, 2003, 50(7): 749–750.

Kalthoff FS, Chung J, Stuetz A. Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells[J]. Clin Exp Immunol, 2002, 130(1): 85–92.

Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group[J]. Arch Dermatol, 1995, 131(12): 1403–1408.

Kwon CY, Lee B, Kim S, et al. Effectiveness and safety of herbal medicine for atopic dermatitis: an overview of systematic reviews[J]. Evid Based Complement Alternat Med, 2020, 2020: 4104692.

Meister S, Plouffe DM, Kuhlen KL, et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery[J]. Science, 2011, 334(6061): 1372–1377.

Kittaka H, Tominaga M. The molecular and cellular mechanisms of itch and the involvement of TRP channels in the peripheral sensory nervous system and skin[J]. Allergol Int, 2017, 66(1): 22–30.

Twycross R, Greaves MW, Handwerker H, et al. Itch: scratching more than the surface[J]. QJM: Int J Med, 2003, 96(1): 7–26.

Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity[J]. Biochem Biophys Res Commun, 2009, 388(4): 621–625.

Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice[J]. Nat Immunol, 2004, 5(7): 752–760.